Trichy Daily

Cutaneous T-Cell Lymphoma Pipeline Analysis Shows a Tremendous Growth Opportunities for the Upcoming Years in the Domain

 Breaking News
  • No posts were found

Cutaneous T-Cell Lymphoma Pipeline Analysis Shows a Tremendous Growth Opportunities for the Upcoming Years in the Domain

July 16
04:01 2021
Cutaneous T-Cell Lymphoma Pipeline Analysis Shows a Tremendous Growth Opportunities for the Upcoming Years in the Domain

Cutaneous T-Cell Lymphoma Pipeline
DelveInsight’s Cutaneous T-Cell Lymphoma (CTCL) pipeline report gives extensive insights into the Cutaneous T-Cell Lymphoma (CTCL) pipeline environment, including 50+ companies and 50+ pipeline drugs. It also includes clinical and nonclinical stage products in the pipeline drug profiles.

DelveInsight’s Cutaneous T-Cell Lymphoma (CTCL) pipeline report gives extensive insights into the Cutaneous T-Cell Lymphoma (CTCL) pipeline environment, including 50+ companies and 50+ pipeline drugs. It also includes clinical and nonclinical stage products in the pipeline drug profiles.

Some of the Important Highlights from the Cutaneous T-Cell Lymphoma Pipeline Report

  • There are currently 50+ drugs in the pipeline for the treatment of Cutaneous T-Cell Lymphoma.

  • Cutaneous T-Cell Lymphoma pipeline comprises therapies which are in different stages of clinical phase include Naloxone Hydrochloride Lotion, SGX301, Atezolizumab, Pembrolizumab, ASTX 660, Durvalumab, LB1901, Tinostamustine and others and are expected to get available in the upcoming years.

  • Key pharmaceutical players which are testing their drug candidates for CTCL treatment include Elorac, Soligenix, Hoffmann-La Roche, Merck Sharp & Dohme Corp, Otsuka Pharmaceutical Co., Ltd, AstraZeneca, Legend Biotech USA Inc, Mundipharma-EDO GmbH, among others.

  • Soligenix, Inc. announced in January 2021 that it had signed an exclusive Supply, Distribution, and Services Agreement with Daavlin. The regulatory and commercial strategy for SGX301 (synthetic hypericin) for the treatment of Cutaneous T-Cell Lymphoma includes ensuring long-term supply and distribution of a commercially ready light device.

  • Soligenix announced in April 2020 that the European Patent Office had granted the divisional patent application titled “Formulations and Methods of Treating Skin Conditions.” The granted claims concern the therapeutic application of synthetic hypericin in the treatment of Cutaneous T-Cell Lymphoma.

  • Apart from SGX301, Naloxone Hydrochloride Lotion which is developed by Elorac is in Phase III of development for CTCL treatment.

To get an overview, what does cutaneous t-cell lymphoma looks like, request sample @ Cutaneous T-Cell Lymphoma Types

Cutaneous T-Cell Lymphoma: Overview

Cutaneous T-Cell Lymphoma (CTCL) is a rare type of cancer that begins in T cells (T lymphocytes), which are white blood cells. Normally, these cells assist your body’s immune system in fighting germs. T cells in Cutaneous T-Cell Lymphoma develop abnormalities that cause them to attack the skin.

There are two subtypes of Cutaneous T-Cell Lymphoma: Mycosis Fungoides (MF) and Sézary Syndrome

Cutaneous T-Cell Lymphoma Symptoms

Dry skin, itching (which can be severe), a red rash, and swollen lymph nodes are all symptoms of Cutaneous T-Cell Lymphoma. Men are more likely to get affected by the disease than women. It typically strikes men in their 40s, 50s, and 60s. The majority of CTCL patients experience only skin symptoms.

Cutaneous T-Cell Lymphoma Treatment

The level of skin involvement, the type of skin lesion, and whether the cancer has spread to the lymph nodes or other internal organs are all aspects taken into account when determining the best treatment for each patient.

Cutaneous T-Cell Lymphoma Pipeline Analysis: Drug Profiles

SGX301: Soligenix

Product Description

SGX301 (synthetic hypericin) is a revolutionary, first-in-class photodynamic treatment that activates cells with safe visible light. Synthetic hypericin, the active ingredient in SGX301, is a powerful photosensitizer that is administered topically to skin lesions, taken up by malignant T-cells, and then triggered by fluorescent light 16 to 24 hours later.

Phase III

NCT02448381: Soligenix began a Phase 3 multicenter, randomised, double-blind, placebo-controlled research in December 2015 to see if topical SGX301 (Synthetic Hypericin) and fluorescent bulb-light irradiation for the treatment of Cutaneous T-Cell Lymphoma were effective.

For more information on the emerging drugs and companies, visit Cutaneous T-Cell Lymphoma Pipeline Analysis

Cutaneous T-Cell Lymphoma Pipeline Therapies and Key Companies

  • Elorac: Naloxone Hydrochloride Lotion

  • SGX301: Soligenix

  • Atezolizumab: Hoffmann-La Roche

  • Pembrolizumab: Merck Sharp & Dohme Corp

  • ASTX 660: Otsuka Pharmaceutical Co., Ltd

  • Durvalumab: AstraZeneca

  • LB1901: Legend Biotech USA Inc

  • Tinostamustine: Mundipharma-EDO GmbH

Cutaneous T-Cell Lymphoma Therapeutics Assessment

  • By Product Type

    • Monotherapy

    • Combination Therapy

  • By Stage

    • Discovery

    • Pre-Clinical

    • Phase I

    • Phase II

    • Phase III

    • Pre-registration

  • By Route of Administration

    • Inhalation

    • Intravenous

    • Oral

    • Subcutaneous

  • By Molecule Type

    • Small Molecule

    • Stem Cell Therapy

    • Gene Therapy

  • Targets

    • Immune System

    • Multiple Kinase

  • By Mechanism of Action

    • Protease Inhibitors

    • Immunomodulatory

Scope of the Report

Coverage: Global

Cutaneous T-Cell Lymphoma Key Players: Elorac, Soligenix, Hoffmann-La Roche, Merck Sharp & Dohme Corp, Otsuka Pharmaceutical Co., Ltd, AstraZeneca, Legend Biotech USA Inc, Mundipharma-EDO GmbH,among others

Cutaneous T-Cell Lymphoma Pipeline Therapies: Naloxone Hydrochloride Lotion, SGX301, Atezolizumab, Pembrolizumab, ASTX 660, Durvalumab, LB1901, Tinostamustine, and others

Table of Contents

1.

Introduction

2.

Executive Summary

3.

Cutaneous T-Cell Lymphoma : Overview

4.

Cutaneous T-Cell Lymphoma – Analytical Perspective In-depth Commercial Assessment

5.

Cutaneous T-Cell Lymphoma Pipeline Therapeutics

6.

Cutaneous T-Cell Lymphoma Late Stage Products (III)

7.

Cutaneous T-Cell Lymphoma Mid Stage Products (Phase II)

8.

Cutaneous T-Cell Lymphoma Early Stage Products (Phase I)

9.

Cutaneous T-Cell Lymphoma Therapeutic Assessment

10.

Cutaneous T-Cell Lymphoma Inactive Products

11.

Cutaneous T-Cell Lymphoma Company-University Collaborations (Licensing/Partnering) Analysis

12.

Cutaneous T-Cell Lymphoma – Key Companies

13.

Cutaneous T-Cell Lymphoma – Key Products

14.

Cutaneous T-Cell Lymphoma – Unmet Needs

15.

Cutaneous T-Cell Lymphoma – Market Drivers and Barriers

16.

Cutaneous T-Cell Lymphoma – Future Perspectives and Conclusion

17.

Cutaneous T-Cell Lymphoma – Analyst Views

18.

Appendix

19.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts

Key questions answered in the Cutaneous T-Cell Lymphoma Pipeline Report

  • What therapy options are available for Cutaneous T-Cell Lymphoma?

  • How many drug companies are developing treatments for Cutaneous T-Cell Lymphoma?

  • Which of these companies’ drugs are the most popular?

  • What is the total number of Cutaneous T-Cell Lymphoma medicines produced by each company?

  • How many medications in the Cutaneous T-Cell Lymphoma pipeline are in the early stages of development, the mid stages of development, or the late stages of development?

  • How many of the therapies in development can be used on their own or in combination with other treatments?

  • What are the most significant industry-industry and industry-academy collaborations, mergers & acquisitions, and licencing practises affecting Cutaneous T-Cell Lymphoma?

Related Reports

Peripheral T-Cell Lymphoma Pipeline Insights 

Get comprehensive analysis of Pruritus pipeline therapies and key companies including Acrotech Biopharma LLC, Seattle Genetics, Inc., CerRx, Inc., Verastem, Inc., Kura Oncology, Inc.,  among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/

Related Articles